Quartette is owned by Teva Branded Pharm.
Quartette contains Ethinyl Estradiol; Levonorgestrel.
Quartette has a total of 2 drug patents out of which 0 drug patents have expired.
Quartette was authorised for market use on 28 March, 2013.
Quartette is available in tablet;oral dosage forms.
Quartette can be used as prevention of pregnancy.
The generics of Quartette are possible to be released after 11 March, 2029.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8450299||TEVA BRANDED PHARM||Methods of hormonal treatment utilizing ascending-dose extended cycle regimens|| |
(2 years from now)
|US8415332||TEVA BRANDED PHARM||Methods of hormonal treatment utilizing ascending-dose extended cycle regimens|| |
(6 years from now)
Market Authorisation Date: 28 March, 2013
Treatment: Prevention of pregnancy
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic